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Abstract		
Chronic	 inflammation	 is	 a	 common	 factor	 in	 the	 development	 of	 many	 gastrointestinal	
malignancies.	 Examples	 include	 inflammatory	 bowel	 disease	 predisposing	 to	 colorectal	
cancer,	Barrett’s	esophagus	as	a	precursor	of	esophageal	adenocarcinoma	and	Helicobacter	
pylori-induced	gastric	cancer.	
The	classical	activation	pathway	of	NF-κB	signaling	has	been	identified	as	regulating	several	
sporadic	 and	 inflammation-associated	 gastrointestinal	 tract	 malignancies.	 Emerging	
evidence	 suggests	 that	 the	 alternative	 NF-κB	 signaling	 pathway	 also	 exerts	 a	 distinct	
influence	on	these	processes.	This	review	brings	together	current	knowledge	of	the	role	of	
the	 alternative	 NF-κB	 signaling	 pathway	 in	 the	 gastrointestinal	 tract,	 with	 a	 particular	
emphasis	on	inflammation-associated	cancer	development.	
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Introduction		
Members	 of	 the	 Nuclear	 Factor	 κ-light-chain-enhancer	 of	 activated	 B	 cells	 (NF-κB)	 family	
were	 initially	 described	 as	 transcription	 factors	 in	 B	 lymphocytes	 in	 1986(68).	 Since	 then,	
they	have	been	shown	to	be	widely	expressed	and	are	conserved	across	both	vertebrates	
and	invertebrates(6,	27).	
The	conventional	model	of	NF-κB	signaling	proposes	two	main	arms	of	the	pathway.	These	
share	 similar	 features,	 but	 are	 triggered	 independently	 and	 activate	 different	 target	
genes(76).	The	classical	 (canonical)	NF-κB	activation	pathway	 is	 triggered	by	Th1	cytokines	
and	is	typified	by	the	action	of	RelA(p65)–NF-κB1(p50)	heterodimers,	whilst	the	alternative	
(non-canonical)	 activation	 pathway	 signals	 through	 the	 adaptor	 protein	 NF-κB-inducing	
kinase	(NIK).	Activation	of	this	mechanism	leads	to	nuclear	translocation	of	transcriptionally	
active	 v-rel	 avian	 reticuloendotheliosis	 viral	 oncogene	 homolog	 B	 (RelB)–NF-κB2(p52)	
heterodimers.	
Signaling	through	either	pathway	can	influence	multiple	different	cellular	functions	and	can	
exert	 effects	 that	 may	 appear	 contradictory.	 For	 example,	 both	 pro-	 and	 anti-apoptotic	
effects,	as	well	as	proliferation(18)	and	senescence(70)	signals	have	been	attributed	to	the	
classical	activation	pathway	of	NF-κB	signaling.	Because	of	 the	wide	variation	 in	outcomes	
following	pathway	activation,	it	is	difficult	to	extrapolate	the	effects	of	NF-κB	signaling	from	
one	 context	 to	 another.	 Classical	 pathway	 NF-κB	 signaling	 has	 been	 identified	 as	 a	 key	
regulator	of	inflammation	associated	carcinogenesis	in	several	tissues	since	the	early	2000s	
when	Greten	et	al	demonstrated	increased	sensitivity	to	colitis	associated	carcinogenesis	in	
mice	lacking	IKK-ß	in	intestinal	epithelial	cells(31),	and,	almost	simultaneously	Pikarsky	et	al	
identified	 a	 similar	 increase	 in	 tumour	 burden	 in	 Mdr2	 mice	 lacking	 IKK-ß	 in	
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hepatocytes(60).	More	recent	evidence	has	established	that	alternative	activation	pathway	
NF-κB	 signaling	 is	 also	 important	 during	 the	 development	 of	 several	 gastrointestinal	 (GI)	
pathologies	 in	mouse	and	man.	This	article	 seeks	 to	 review	this	evidence	and	 to	establish	
questions	for	future	research.	
Literature	search	strategy		
A	systematic	search	of	the	English	language	literature	listed	in	the	PubMed	database	up	to	
5th	November	2015	was	performed	using	the	following	search	terms:	
(NF-κB2	OR	NFκB2	OR	NF-kappaB2	OR	NFkappaB2	OR	NF-kB2	OR	NFkB2	OR	p52	OR	p100	OR	
"alternative	 NF-κB"	 OR	 "alternative	 NFκB"	 OR	 "alternative	 NF-kappaB"	 OR	 "alternative	
NFkappaB"	OR	 "alternative	NF-kB"	OR	 "alternative	NFkB"	OR	 "non-canonical"	OR	 relB	OR	
NIK	OR	IKKa	OR	IKKalpha	OR	MAP3K14	OR	CHUK)	AND	(stomach	OR	gastric	OR	intestine	OR	
intestinal	OR	gastrointestinal	OR	 colon	OR	colonic	OR	 colorectal	OR	 colitis	OR	Crohn's	OR	
bowel	OR	oesophagus	OR	oesophageal	OR	esophagus	OR	esophageal	OR	Barrett's).		
This	search	generated	449	results,	of	which	159	articles	were	retained	following	review	of	
titles	and	abstracts.	The	full	 texts	of	 these	articles	were	acquired	and	used	as	the	basis	of	
this	 article;	 retrieved	 article	 reference	 lists	 were	 searched	 manually	 for	 other	 relevant	
literature.	The	scope	of	the	article	has	been	limited	to	the	importance	of	the	alternative	NF-
κB	 signaling	 pathway	 in	 the	 gastrointestinal	 tract,	 particularly	 during	 the	 development	 of	
cancers	and	pre-malignant	pathologies.	Articles	discussing	the	liver	and	pancreas	only	have	
been	excluded.	
The	alternative	NF-κB	activation	pathway	
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The	NF-κB/Rel	family	includes	five	members:	RelA(p65),	c-Rel,	RelB,	NF-κB1(p50/p105),	and	
NF-κB2(p52/p100).	 Each	possesses	a	 structurally	 conserved	300	amino-acid	 sequence;	 the	
REL	homology	 domain	 (RHD).	 In	 the	 unstimulated	 state,	 these	 proteins	 pool	 as	 homo-	 or	
heterodimers	 (of	which	 there	 are	 at	 least	 15	 known	 combinations),	 predominantly	within	
the	cytoplasm(71).	Some	of	these	dimers	function	exclusively	in	the	classical	NF-κB	signaling	
pathway	 (figure	 1a)	 and	 are	 beyond	 the	 scope	 of	 this	 article.	 Alternative	 NF-κB	 pathway	
activation	 leads	 to	 translocation	 of	 NF-κB2(p52)/RelB	 heterodimers	 into	 the	 nucleus,	
following	which	NF-κB2(p52)	and	RelB	directly	influence	gene	transcription.	
NF-κB	mediated	transcription	is	regulated	by	the	inhibitors	of	NF-κB	(IκB)	(IκBα,	IκBβ,	IκBε,	
and	Bcl-3)	which	are	peptides	that	bind	NF-κB	protein	dimers	through	residues	containing	6	
to	 7	 ankyrin	 repeats.	 Interaction	 of	 IκB	 proteins	 with	 NF-κB	 protein	 dimers	 prevents	 the	
nuclear	 translocation	 of	 the	 NF-κB	 protein	 dimers.	 NF-κB2	 is	 synthesized	 as	 a	 100kDa	
protein,	p100,	which	has	a	RHD	within	its	N-terminus	and	a	seven	ankyrin	repeat	domain	at	
its	C-terminus	which	confers	intrinsic	IκB	activity	(figure	1b)(55).	
Alternative	pathway	NF-κB	activation	is	characterized	by	processing	of	p100	into	p52,	both	
of	which	dimerize	with	RelB	(Figure	1b).	p100	is	processed	by	at	least	two	kinases,	NIK	and	
IκB	kinase	α	 (IKKα).	These	kinases	can	be	activated	by	 ligand	 interaction	with	several	 cell-
surface	 receptors,	 including	 CD40	 ligand	 binding	 to	 CD40,	 B-cell	 activating	 factor	 (BAFF)	
binding	 to	 its	 receptors,	 Lymphotoxin	 β	 interacting	 with	 LTβR,	 lipopolysaccharide	 (LPS)	
binding	to	Toll-like	receptor	4	(TLR4)	and	Receptor	activator	of	nuclear	factor	kappa-B	ligand	
(RANKL)	 binding	 to	 RANK(21).	 The	 pathway	 can	 also	 be	 activated	 by	 oncogenic	 viruses	
including	Epstein-Barr	virus(48).		
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Upon	 ligand	 binding,	 tumor	 necrosis	 factor	 receptor-associated	 factors	 (TRAFs;	 such	 as	
TRAF2	 and	 TRAF3)	 are	 recruited	 either	 directly	 or	 via	 other	 adaptor	 proteins	 to	 the	
intracellular	domain	of	the	activated	receptor.	 	Unlike	TRAF2	and	TRAF5	that	also	regulate	
classical	NF-κB	signaling,	TRAF3	only	regulates	the	alternative	NF-κB	signaling	pathway	and	
directly	 binds	 to	 NIK,	 regulating	 NIK	 turnover(31).	 NIK	 is	 continually	 degraded	 by	 the	
proteasome	 as	 a	 result	 of	 polyubiquitination	 by	 the	 cellular	 inhibitors	 of	 apoptosis	 (c-IAP	
1,2)/E2	 ligase	 complex	 that	 is	 also	 recruited	 to	 TRAF3	 (figure	 1b).	 	 As	 a	 result	 of	 TRAF3	
complex	 recruitment	 to	 the	 activated	 receptor,	 TRAF3	 is	 targeted	 for	 degradation	 by	 the	
proteasome	 which	 allows	 NIK	 to	 accumulate	 in	 the	 cytosol	 (figure	 1c)(60).	 Cytosol	
accumulated	NIK	becomes	phosphorylated	at	 threonine	559	by	an	 incompletely	described	
mechanism	 that	may	 involve	both	autophosphorylation(31),	 and	phosphorylation	via	 zinc-
finger-protein-91(60).	 Subsequently,	 Thr559-phospho-NIK	 phosphorylates	 p100	 at	 serine	
(Ser)	 residues	866	and	870	acting	as	a	docking	molecule	 for	 recruitment	of	 IKKα	 to	p100.	
Recruitment	of	IKKα	leads	to	phosphorylation	of	the	N-terminus	of	NF-κB2(p100)	at	Ser	99,	
108,	 115	 and	 123	 and	 at	 C-terminal	 Ser	 872.	 Beta-transducin	 repeat-containing	 protein	
(beta-TrCP),	 a	 component	 of	 the	 SCF	 ubiquitin	 ligase	 complex	 is	 then	 recruited	 to	
phosphorylated	NF-κB2(p100)	 leading	to	polyubiquitination	of	NF-κB2(p100)	at	 lysine	 (Lys)	
855	which	targets	NF-κB2	for	partial	proteasomal	degradation,	leading	to	generation	of	NF-
κB2(p52)(82).	
Activation	of	the	alternative	NF-κB	signaling	pathway	is	generally	slower	(~6-8	hours)	than	
the	 classical	 activation	 pathway,	 leading	 to	 a	 delayed	 but	 sustained	 response	 which	
integrates	 with	 the	 acute-phase	 (~1.5	 hours)	 response	 driven	 by	 classical	 NF-κB	 pathway	
activation(21,	64).	Emerging	evidence	supports	the	concept	that	classical	and	alternative	NF-
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κB	 activation	 pathways	 interact	 to	 induce	 coordinated	 and	 sustained	 immunological	
responses.	Banoth	and	colleagues	recently	used	systems	level	analysis	to	identify	stimulus-
specific	crosstalk	between	the	TLR4-activated	canonical	NF-κB	activation	pathway	and	LTβR-
induced	alternative	NF-κB	activation	pathway	signaling.	They	identified	a	positive-feedback	
loop	 that	 sustained	 the	 NF-κB	 response.	 Using	 mouse	 embryonic	 fibroblasts,	 they	
demonstrated	 that	 LTβR	 prolonged	 the	 TLR4-induced	 RelA	 response,	 by	 targeting	 newly-
synthesized	 p100	 for	 processing	 to	 p52,	 allowing	 formation	 of	 p65(RelA)-p52(NF-κB2)	
dimers.	This	led	to	increased	expression	of	pro-inflammatory	cytokines	and	chemokines(10).	
Understanding	 the	 integration	 of	 different	 mechanisms	 of	 NF-κB	 activation	 is	 a	 key	
challenge	for	this	field.	
Role	of	the	alternative	NF-κB	activation	pathway	in	gut	development	and	repair	
Whilst	 the	classical	NF-κB	activation	pathway	components	RelA	and	c-Rel	 can	be	 found	 in	
many	tissues	and	cell	types,	in	health	the	expression	of	alternative	pathway	NF-κB	sub-units	
has	 more	 frequently	 been	 demonstrated	 in	 cells	 of	 the	 immune	 system	 where	 there	 is	
strong	 evidence	 that	 they	 play	 pivotal	 roles	 in	 the	 development	 of	 an	 effective	 immune	
system.	For	examble	RelB-/-	mice	are	deficient	in	dendritic	cells	and	develop	a	spontaneous	
multi-organ	autoimmune	phenotype(16,	60,	80),	whilst	Nfkb2-/-	mice	have	structural	defects	
in	 the	 spleen	and	 lymph	nodes	with	 irregular	B-cell	 areas	and	an	absence	of	perifollicular	
and	 mantle	 zones.	 This	 leads	 to	 a	 reduced	 number	 of	 	 B-cells,	 but	 with	 normal	 B-cell	
maturation.	 In	 keeping	 with	 this,	 Nfkb2-/-	 mice	 also	 exhibit	 impaired	 antigen	 specific	
antibody	production(17,	80).	
Observations	from	unstimulated	transgenic	mice	have	also	offered	insight	into	an	epithelial	
role	 for	 the	 alternative	 activation	 pathway	 of	 NF-κB	 signaling.	Mice	 that	 lack	 Ikka,	 which	
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encodes	 the	 pathway	 regulating	 kinase	 IKKα,	 survive	 until	 birth,	 but	 die	 shortly	 after	
delivery.	These	animals	are	born	with	marked	cutaneous	and	skeletal	deformities	including	
markedly	 thickened	 skin(36,	 44,	 74).	 A	 similar	 phenotype	 is	 observed	 in	 mice	 with	
keratinocyte	 specific	 deletion	 of	 Ikka(26)	 suggesting	 that	 this	 phenotype	 is	 due	 to	 the	
disruption	of	alternative	pathway	NF-κB	activation	in	the	epithelial	compartment.	
More	 recent	 data	 have	 also	 demonstrated	 constitutive	 expression	 of	 RelB	 within	 small	
intestinal	 Peyer’s	 patches(45)	 and	 of	 RelB	 and	 NF-κB2	 (p100)	 in	 murine	 gastric	
epithelium(15).	
Animal	models	suggest	that	the	alternative	NF-κB	activation	pathway	components	NIK,	NF-
κB2	 and	 RelB	 are	 required	 for	 the	 normal	 development	 of	 small	 intestinal	 Peyer’s	
patches(24,	83).	Peyer’s	patches	consist	predominantly	of	immune	cells	which	exist	in	close	
association	 with	 the	 specialized	 ‘dome’-like	 epithelium	 described	 as	 follicle-associated	
epithelium	 (FAE).	 The	 presence	 of	 RelB-expressing	 cells	 also	 appears	 essential	 for	 the	
differentiation	of	enterocytes	 into	microfold	cells	 (M-cells)	which	represent	approximately	
5%	 of	 epithelial	 cells	 within	 FAE.	 Functionally,	M-cells	 are	 specialized	 to	 perform	 luminal	
antigen	sampling	and	immune	priming(49).	M-cells	have	been	implicated	in	the	initiation	of	
granulomatous	 lesions	 in	 Crohn’s	 disease(11)	 and	 are	 thought	 to	 influence	 responses	 to	
gastrointestinal	 infections(23,	 73),	 and	 colorectal	 carcinogenesis(3,	 51).	 Tahoun	 and	
colleagues	 found	 that	 stimulation	 of	 RelB-expressing	 FAE	 enterocytes	 with	 Salmonella	
enterica	 Typhimurium	 triggered	 autocrine	 activation	 by	 RANK	 ligand-RANK	 interaction	
induced	 the	 transcription	 factor	 Snail	 family	 zinc	 finger-2	 (Slug)	 and	 resulted	 in	
transdifferentiation	into	M-cells(73).	The	expression	of	glycoprotein-2	(GP2),	a	key	receptor	
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expressed	on	mature	M-cells	also	appears	to	be	dependent	on	the	nuclear	translocation	of	
RelB(41).		
Whilst	 there	 is	 substantial	 evidence	 that	 RelB	 is	 involved	 in	 the	 development	 of	 Peyer’s	
patches	 and	 M-cells	 within	 FAE,	 the	 mechanisms	 involved	 remain	 unclear.	 Wang	 and	
colleagues	demonstrated	that	Peyer’s	patch	development	was	dependent	on	stimulation	of	
TNFR	and	LTβR(78),	however	 the	precise	 ligands	 for	 these	 receptors	and	 the	downstream	
effects	of	signaling	via	this	pathway	during	the	development	of	Peyer’s	patches	have	not	yet	
been	defined.		
There	 is	 also	 evidence	 that	 alternative	 pathway	 NF-κB	 signaling	 may	 influence	 gastric	
epithelial	 homeostasis.	 Mice	 lacking	 the	 COOH-terminal	 ankyrin	 repeat	 domain	 of	 p100	
synthesize	a	 truncated	 form	of	NF-κB2,	which	 lacks	 the	 IκB	activity	of	p100,	but	 is	able	 to	
dimerize	with	other	NF-κB	protein	 family	members	 and	 can	 translocate	 to	 the	nucleus	 to	
influence	 transcription.	 This	models	 unimpeded	 alternative	 pathway	NF-κB	 activation	 and	
leads	to	persistent	translocation	of	NF-κB2-containing	dimers	to	the	nucleus.	These	animals	
exhibit	massive	gastric	antral	hyperplasia,	have	increased	lymphocyte	proliferation	and	die	
during	early	postnatal	life	due	to	complications	following	gastric	outlet	obstruction(38).	
Alternative	pathway	NF-κB	signaling	in	cancers	of	the	gastrointestinal	tract	
Inflammatory	mediators	 influence	many	cellular	functions	that	may	promote	development	
of	 a	malignant	 phenotype(32).	 Since	 NF-κB	 signaling	 regulates	 innate	 immune	 responses,	
influencing	the	expression	of	a	set	of	target	genes	in	epithelial	and	immune	compartments	
including	cytokines	 (e.g.	TNF,	 interleukin	 (IL)-6	and	 IL-1β)(35,	46,	70),	 their	 receptors	 (TNF	
superfamily	receptors)	and	other	inflammatory	mediators,	including	cell	adhesion	molecules	
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such	 as	 vascular	 cell	 adhesion	 protein	 1	 (VCAM-1)(37,	 65)	 as	 well	 as	 genes	 involved	 in	
regulating	 the	 cell	 cycle	 such	 as	 cyclins	 and	 cyclin-dependent	 kinases(33,	 39,	 43),	 it	 is	
unsurprising	that	these	processes	also	influence	tumorigenesis.	
The	majority	 of	 studies	 investigating	NF-κB	 and	 cancers	 of	 the	 gastrointestinal	 tract	 have	
focused	upon	the	classical	activation	pathway	family	members	NF-κB1,	RelA	(p65)	and	c-Rel.	
However	 there	 is	 emerging	 evidence	 that	 alternative	 NF-κB	 activation	 pathway	 family	
members	also	play	important	roles	during	carcinogenesis	throughout	the	GI	tract.	
Esophageal	cancer	
Two	 histological	 subtypes	 of	 esophageal	 cancer	 exist,	 both	 of	 which	 develop	 on	 a	
background	 of	 chronic	 inflammation.	 Esophageal	 squamous	 carcinoma	 is	 associated	 with	
inflammation	 induced	 by	 extrinsic	 stimuli	 including	 cigarette	 smoking	 and	 alcohol	
consumption.	 Esophageal	 adenocarcinoma	 is	 also	 associated	 with	 these	 extrinsic	 risk	
factors,	 but	 is	 also	 associated	 with	 chronic	 gastroesophageal	 reflux,	 and	 occurs	 on	 a	
background	 of	 columnar	 metaplasia	 (Barrett’s	 esophagus).	 The	 epidemiology	 and	
pathophysiology	 of	 these	 conditions	 are	 distinct,	 with	 the	 incidence	 of	 both	 conditions	
increasing	in	western	populations.		
In	normal	 squamous	esophageal	 tissue,	 the	expression	of	NF-κB	proteins	 is	 relatively	 low.	
However	 tissue	 samples	 from	patients	with	 esophageal	 squamous	 cell	 carcinoma	 showed	
increased	expression	of	NF-κB1(p50/105),	NF-κB2(p52/100)	 and	RelA	up	 to	18-fold(40).	 In	
addition	the	anti-tumor	activity	of	the	hypo-methylating	chemotherapeutic	drug	decitabine	
has	been	associated	with	increased	expression	of	NF-κB2(47).	
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Few	investigators	have	addressed	the	role	of	alternative	pathway	NF-κB	signaling	in	gastro-
esophageal	 reflux	disease,	Barrett’s	esophagus	or	esophageal	adenocarcinoma	 in	humans,	
however	 a	 recent	 study	 examined	 the	 role	 of	 reflux	 and	 smoking	 on	 the	 expression	 of	
alternative	 pathway	 NF-κB	 signaling	 components	 in	 the	 esophageal	 epithelium	 of	 mice.	
Using	immunohistochemistry	it	was	demonstrated	that	the	abundance	of	NIK	was	increased	
in	the	presence	of	either	cigarette	smoke	alone	or	reflux	alone(2).	One	of	the	challenges	of	
investigating	the	function	of	NF-κB	pathways	is	the	need	to	differentiate	the	abundance	of	
proteins	 that	 signal	 within	 the	 pathway	 and	 their	 functional	 effects.	 These	 data	 provide	
inconclusive	 evidence	 that	 alternative	 pathway	 NF-κB	 signaling	 is	 involved	 in	 esophageal	
adenocarcinoma	development,	but	support	the	need	for	further	investigation	of	alternative	
pathway	NF-κB	signaling	in	this	context.	
Gastric	Cancer	
The	 most	 important	 etiological	 factor	 during	 gastric	 carcinogenesis	 is	 infection	 with	
Helicobacter	 pylori(1,	 25,	 30,	 56,	 58).	 H.	 pylori	 infection	 results	 in	 stereotypical	 pre-
malignant	 gastric	 pathology	 progressing	 from	 atrophic	 gastritis	 through	 metaplasia	 into	
dysplasia	 and	 cancer.	 In	 humans	 this	 process	 develops	 over	 several	 decades;	 mouse	
infection	with	the	closely	related	bacterium	Helicobacter	felis	recapitulates	this	sequence	of	
pathology	 over	 an	 accelerated	 timescale.	 We	 recently	 showed	 that,	 despite	 heavy	
colonization	 with	H.	 felis,	Nfkb2-/-	 mice	 developed	 minimal	 inflammatory	 cell	 infiltration,	
demonstrated	a	blunted	cytokine	 response	and	did	not	develop	 the	pre-malignant	 lesions	
associated	with	chronic	H.	felis	infection(15)	(Figure	2a-d).		
Other	data	have	demonstrated	in-vitro	relevance	for	this	pathway	in	response	to	H.	pylori	in	
both	gastric	epithelial	 and	 immune	cell	 culture	 systems(15,	56,	58).	Hirata	and	colleagues	
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showed	that	IKKα	accumulates	in	AGS	cells	following	H.	pylori	infection,	but	this	did	not	lead	
to	 NF-κB2(p100)	 processing	 to	 NF-κB2(p52).	 The	 consequences	 of	 this	 are	 not	 clear,	
however	 it	 has	 been	 postulated	 that	 accumulation	 of	 cytosolic	 NF-κB2(p100)	may	 inhibit	
nuclear	 NF-κB2(p52)	 interaction	 with	 chromatin,	 leading	 to	 an	 altered	 transcriptional	
fingerprint(34).	
Separately,	H.	pylori	activation	of	NF-κB	was	shown	to	occur	via	a	pathway	requiring	IKKα,	
IKKβ,	 and	 NIK	 in	 MKN45	 and	 KATO	 III	 human	 gastric	 cancer	 cell	 lines.	 In	 this	 context,	
activation	 of	 NIK	 also	 required	 signaling	 via	 the	 adapter	 proteins	 TRAF2	 and	 TRAF6(50).	
Further	evidence	for	the	involvement	of	NIK	was	provided	by	Neumann	and	colleagues[41]	
who	demonstrated	that	activation	of	NF-κB	by	H.	pylori	required	the	formation	of	a	complex	
between	p21-activated	kinase	1	(PAK1)	and	NIK(54).		
In	addition	 to	 the	evidence	 that	H.	pylori	can	activate	NF-κB	via	 the	alternative	activation	
pathway	 in	 epithelial	 tissue,	 in-vitro	 processing	 of	 NF-κB2(p100)	 to	 NF-κB2(p52)	 has	 also	
been	 demonstrated	 in	 B	 lymphocytes	 in	 response	 to	 H.	 pylori(57).	 This	 may	 have	
implications	for	the	development	of	gastric	MALT	lymphomas.	
Further	 evidence	 that	 classical	 and	 alternative	 pathway	 NF-κB	 activation	 is	 relevant	 to	
Helicobacter-induced	 pathology	 comes	 from	 the	 evidence	 that	 clarithromycin,	 one	 of	 the	
antibiotics	 used	 most	 frequently	 to	 eradicate	 H.	 pylori,	 modulates	 H.	 pylori-induced	
activation	of	NF-κB	via	both	activation	pathways	in	gastric	cancer	cells(59).	
Colorectal	cancer	
Sporadic	 colorectal	 cancers	most	 commonly	 develop	 from	 adenomatous	 polyps(9).	 These	
lesions	develop	as	a	 consequence	of	 the	acquisition	of	 stereotypical	mutations	over	 time.	
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They	occur	in	an	otherwise	non-inflamed	colonic	mucosa,	but	an	inflammatory	response	to	
adenoma	 development	 is	 frequently	 identified.	 Despite	 this,	 few	 data	 regarding	 the	
importance	 of	 the	 alternative	 activation	 pathway	 of	 NF-κB	 signaling	 during	 sporadic	
colorectal	carcinogenesis	exist.		
Amongst	the	best	characterized	pathways	involved	in	colorectal	carcinogenesis	is	the	WNT	
signaling	pathway.	 	Activation	of	 this	pathway	 leads	 to	 stabilization	of	β-catenin,	which	 is	
observed	in	many	colonic	adenomas.	There	is	increasing	evidence	for	crosstalk	between	the	
NF-κB	and	WNT	signaling	pathways,	with	evidence	that	activation	of	NF-κB	pathways	may	
accelerate	 the	 loss	of	APC	during	 colorectal	 adenoma	development(69).	However	 there	 is	
little	direct	evidence	to	suggest	that	alternative	pathway	NF-κB	signaling	is	involved.	
There	 is	 circumstantial	 evidence	 that	 alternative	 pathway	 NF-κB	 signaling	 may	 exert	 an	
effect	 on	 sporadic	 colonic	 carcinogenesis.	 MicroRNA-518a-3p	 was	 observed	 to	 be	 down-
regulated	in	colon	cancers	in	proportion	to	their	size	and	TNM	stage.	This	microRNA	targets	
NIK	mRNA	for	degradation,	therefore	its	down-regulation	leads	to	increased	NIK	abundance	
and	subsequent	activation	of	NIK	dependent	NF-κB	pathways(61).	In	support	of	this	are	data	
that	have	demonstrated	an	increase	in	IKKα	abundance	in	tissue	samples	from	patients	with	
sporadic	colon	cancer	(19).		
In	 contrast	 to	 sporadic	 colon	 cancer,	 more	 has	 been	 published	 regarding	 the	 impact	 of	
alternative	pathway	NF-κB	signaling	during	the	development	of	colitis-associated	colorectal	
cancer.	Individuals	with	chronic	inflammatory	bowel	disease	(IBD),	including	Crohn’s	disease	
and	 ulcerative	 colitis,	 have	 an	 increased	 risk	 of	 colorectal	 cancer(75).	 In	 these	 patients,	
colorectal	 tumors	 develop	 on	 the	 background	 of	 colonic	 inflammation	 and	 rather	 than	
developing	as	discrete	polyps,	usually	arise	within	fields	of	flat	dysplastic	mucosa(9).	
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The	most	 established	murine	model	 of	 colitis-associated	 cancer	 uses	 a	 single	 dose	 of	 the	
DNA-damaging	 agent	 azoxymethane	 (AOM)	 followed	 by	 several	 doses	 of	 dextran	 sulfate	
sodium	(DSS)	to	induce	chronic	colitis	(AOM/DSS)(20).	We	have	reported	that	Nfkb2-/-	mice	
are	resistant	to	AOM/DSS-induced	colitis-associated	adenoma	development(14).	Transgenic	
mice	developed	fewer	dysplastic	colonic	lesions,	were	less	susceptible	to	DSS-induced	colitis	
(Figure	2i-p),	and	had	a	more	robust	apoptotic	response	following	DNA	damage	compared	
to	wild-type	controls.	
In	 contrast	 to	Nfkb2-/-	mice,	Nlrp12-/-	mice	 exhibited	 increased	 susceptibility	 to	 AOM/DSS	
induced	colitis-associated	colorectal	cancer;	polyps	isolated	from	these	mice	had	increased	
activation	 of	 the	 alternative	 NF-κB	 activation	 pathway.	 Nlrp12-/-	 primary	 dendritic	 cells	
showed	elevated	NIK	expression,	p100	processing	to	p52	and	reduced	abundance	of	TRAF3.	
This	provides	evidence	for	NLRP12	acting	as	a	checkpoint	on	signaling	via	the	alternative	NF-
κB	activation	pathway	during	inflammation	and	tumorigenesis(4).		
Alternative	pathway	NF-κB	signaling	in	conditions	of	the	GI	tract	that	predispose	to	cancer	
Gastrointestinal	tract	infections	
Chronic	bacterial	and	helminth	infections	are	established	risk	factors	for	the	development	of	
malignancy.	The	best-characterized	organism	is	H.	pylori,	which	plays	a	major	role	in	gastric	
carcinogenesis	as	discussed	above.	Several	lines	of	evidence	have	identified	that	alternative	
pathway	NF-κB	signaling	is	important	in	the	host	response	to	gastrointestinal	pathogens.	
Infection	 with	 the	 foodborne	 pathogen	 Salmonella	 Typhimurium	 has	 been	 shown	 to	
promote	the	differentiation	of	M-cells	in	the	small	intestine	through	induction	of	RANK,	and	
its	ligand	RANKL,	leading	to	increased	differentiation	of	M-cells	and	increased	uptake	of	the	
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pathogen.	In	addition	to	the	evidence	described	above	that	S.	Typhimurium	may	induce	M-
cell	transdifferentiation	via	an	alternative	activation	NF-κB	pathway	dependent	mechanism	
Tahoun	 and	 colleagues(73)	 have	 also	 demonstrated	 that	 translocation	 of	 S.	 Typhimurium	
was	significantly	reduced	in	the	presence	of	the	NF-κB	inhibitor	SN50,	suggesting	that	NF-κB	
signaling	 plays	 a	 role	 in	 enhancing	 S.	 Typhimurium	 translocation	across	 the	 epithelium.	
Whilst	 this	 organism	 is	 not	 directly	 associated	with	 gastrointestinal	 carcinogenesis,	 these	
mechanisms	 offer	 a	 paradigm	 by	 which	 other	 carcinogenic	 organisms	 may	 influence	
epithelial	events	via	NF-κB	signaling.		
Banoth	 and	 colleagues	 demonstrated	 that	 C57BL/6	 mice	 infected	 with	 Citrobacter	
rodentium	 developed	 colitis	 with	 epithelial	 accumulation	 of	 p100.	Nfkb2-/-	 mice	 infected	
with	C.	 rodentium	were	more	 susceptible	 to	developing	 colitis	 than	wild-type	mice.	Using	
reciprocal	 bone	 marrow	 transfer	 experiments,	Nfkb2-/-	mice	 given	 wild-type	 mouse	 bone	
marrow	 lost	weight	and	had	100%	mortality	before	day	10,	whereas	wild-type	mice	given	
either	wild-type	or	Nfkb2-/-	bone	marrow	did	not	 lose	weight	or	show	 increased	mortality.	
These	 findings	 indicate	 that	 NF-κB2	 expression	 within	 the	 non-myeloid	 compartment	 is	
involved	in	limiting	the	severity	of	C.	rodentium	associated	colitis(10).		
Alternative	 pathway	 NF-κB	 signaling	 is	 also	 implicated	 in	 the	 orchestration	 of	 immune	
responses	 to	 gastrointestinal	 helminth	 infestation.	 C57BL/6	mice	 generate	 a	marked	 Th2	
immune	 response	 following	 colonization	with	 the	whipworm	Trichuris	muris.	This	 induces	
rapid	expulsion	of	the	helminth	and	clearance	of	infestation	within	35	days	of	colonization.	
In	 contrast,	Nfkb2-/-	 mice	 develop	 a	 chronic,	 persistent	 infestation	 with	 an	 impaired	 Th2	
cytokine	response(8).	Recently,	an	 immunosuppressed	man	with	histoplasmosis	and	extra-
intestinal	 Hymenolepis	 nana	 infection	 was	 found	 to	 possess	 abnormal	 proliferative	 cells	
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which	 displayed	malignant	 characteristics.	Upon	 investigation,	 the	 cells	were	 found	 to	 be	
consistent	with	 tapeworm	 stem	 cells;	 this	 was	 the	 first	 report	 of	 parasite-derived	 cancer	
cells	 in	 a	 human,	 further	 demonstrating	 the	 link	 between	 infection	 and	 cancer,	 and	
highlighting	its	relevance	when	considering	GI	exposure	to	helminths(52).	
Inflammatory	bowel	disease		
Chronic	 idiopathic	 inflammatory	 bowel	 diseases	 that	 affect	 the	 colon	 increase	 an	
individual’s	risk	of	developing	colorectal	cancer	in	proportion	to	the	duration	of	disease	and	
the	extent	of	inflammation(22,	28,	62,	63).	Evidence	suggests	that	treatments	that	decrease	
an	 individual’s	 inflammatory	 burden,	 including	 azathioprine(29)	 and	 5-amino	 salicylic	 acid	
preparations(77)	may	decrease	the	risk	of	developing	colitis-associated	colon	cancer.		
The	alternative	NF-κB	activation	pathway	has	not	to	date	been	targeted	specifically	for	the	
development	of	novel	therapeutics	for	IBD.	This	is	likely	due	to	the	fact	that	most	studies	in	
IBD	 have	 found	 activation	 of	 the	 classical	 activation	 pathway,	 but	 not	 the	 alternative	
pathway(7,	66,	67).	For	example,	Ardite	and	colleagues	used	electromobility	shift	assays	to	
detect	NF-κB	components	in	colonic	biopsy	samples	from	patients	with	active	IBD	who	had	
been	treated	with	steroids.	The	classical	NF-κB	activation	pathway	subunit	p50	was	found	in	
inflamed	 tissue	 from	 IBD	 patients,	 but	 p65,	 p52,	 c-Rel	 and	 RelB	 were	 not	 detected(7).	
Conversely	 Andresen	 et	 al	 examined	 NF-κB	 activity	 by	 EMSA	 and	 supershift	 assays	 and	
demonstrated	p52	DNA	binding	activity	in	colonic	mucosal	samples	from	patients	with	both	
ulcerative	colitis	and	collagenous	colitis(5).	These	articles	demonstrate	the	heterogeneity	of	
NF-κB	signaling	in	tissues.	Part	of	this	variability	is	likely	to	come	from	the	heterogeneity	of	
tissue	samples,	which	contain	cells	of	many	different	 types	 that	may	have	different	NF-κB	
signaling	 states.	 Another	 element	 of	 this	 heterogeneity	 may	 arise	 from	 the	 dynamic	
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shuttling	of	NF-κB	sub-units	between	the	nucleus	and	cytoplasm,	which	has	been	shown	to	
be	 a	 feature	 of	 NF-κB	 activation	 in-vitro(53).	 As	 individual	 cells	 of	 the	 same	 lineage	 in	 a	
tissue	will	be	in	different	phases	of	the	shuttling	process,	this	will	add	to	the	heterogeneity	
of	the	readout	from	EMSA	assays	performed	using	whole	tissue	samples.	
In	contrast	to	the	findings	in	humans,	mouse	models	of	colitis	induced	by	carrageenan	and	
DSS	 have	 demonstrated	 that	 classical	 and	 alternative	 NF-κB	 signaling	 pathways	 are	
activated(12,	13,	 81,	 84)	during	 colonic	 inflammation.	One	of	 the	earliest	 events	 in	 IBD	 is	
thought	 to	 be	 impairment	 of	 enteric	mucosal	 barrier	 function.	We	 have	modeled	 this	 by	
administration	of	 LPS	 from	 Escherichia	 coli	 to	C57BL/6	mice	and	mice	 lacking	NF-κB2.	We	
demonstrated	 that	 Nfkb2-/-	 mice	 were	 more	 resistant	 to	 LPS-induced	 small	 intestinal	
epithelial	 cell	 shedding	 compared	 to	 wild-type	 mice(81)	 (Figure	 2e-h).	 Separately	 and	 as	
described	 above,	 we	 demonstrated	 that	 the	 severity	 of	 DSS-induced	 acute	 colitis	 was	
reduced	in	Nfkb2-/-	mice	relative	to	wild-type	mice(14)(figure	2i-p).	
Our	studies,	and	those	of	Banoth	suggest	that	there	may	be	a	function	for	these	pathways	in	
the	regulation	of	enteral	inflammation,	suggesting	that	targeting	alternative	pathway	NF-κB	
signaling	in	IBD	may	be	a	fruitful	avenue	for	further	research.	
One	 element	 of	 IBD	 therapy	 in	 which	 tangential	 evidence	 for	 alternative	 pathway	 NF-κB	
signaling	has	been	accrued	is	the	role	of	functional	foods.	This	is	of	particular	interest	in	the	
context	of	Crohn’s	disease,	where	dietary	modification	with	liquid	feeding	has	been	shown	
to	offer	therapeutic	benefits,	particularly	in	pediatric	patients.	
A	study	examining	the	role	of	parenteral	nutrition	in	IBD	demonstrated	that	a	lack	of	enteral	
stimulation	 in	 mice	 led	 to	 globally	 reduced	 expression	 of	 NF-κB	 proteins	 in	 Peyer’s	
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patches(42).	Given	the	data	that	implicate	RelB	in	Peyer’s	patch	development,	and	the	role	
that	Peyer’s	patches	play	in	immune	priming,	these	findings	suggest	that	diet-induced	NF-κB	
signaling	may	influence	GI	immune	tolerance.		
In	 contrast	 the	 use	 of	 dietary	 flaxseed	 to	 attempt	 to	 ameliorate	 experimental	 colitis	was	
found	to	exacerbate	DSS-induced	colitis	 in	mice,	which	was	associated	with	an	 increase	 in	
expression	 of	 RelB	 in	 colonic	 tissue(84).	 Together	 these	 studies	 highlight	 the	 functional	
effect	 that	 foods	may	have	on	NF-κB	 alternative	pathway	 signaling	 in	 the	 gastrointestinal	
tract.		
Celiac	Disease	
Gluten	 sensitive	 enteropathy	 (celiac	 disease)	 confers	 an	 increased	 risk	 of	 small	 bowel	
adenocarcinoma	and	small	bowel	lymphoma,	however	due	to	the	rarity	of	these	cases	it	is	
difficult	to	accurately	quantify	the	degree	of	increased	risk(17).	Recent	data	have	identified	
increased	 expression	 of	 NFKB2	 in	 patients	 with	 celiac	 disease,	 irrespective	 of	 their	
adherence	 to	 a	 gluten	 free	 diet(80).	 Currently	 however	 it	 is	 not	 clear	 whether	 this	
association	has	any	impact	on	the	prevalence	or	biology	of	small	bowel	malignancies.	
Potential	for	alternative	pathway	NF-κB	signaling	as	a	therapeutic	drug	target	
One	 of	 the	 aspirations	 of	 research	 into	 this	 field	 is	 to	 identify	 potential	 therapeutic	 drug	
targets	within	the	alternative	NF-κB	activation	pathway.	NF-κB	signaling	has	been	identified	
as	 a	 potentially	 useful	 therapeutic	 target	 in	 cancer	 due	 in	 part	 to	 the	 data	 arising	 from	
animal	models	of	carcinogenesis	reviewed	here,	and	in	part	from	the	in-vitro	evidence	that	
signaling	via	NF-κB	can	 influence	each	of	 the	hallmarks	of	cancer.	Much	of	 the	 interest	 to	
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date	 has	 been	 dominated	 by	 targeting	 the	 classical	 NF-κB	 activation	 pathway,	 however	
direct	targeting	of	the	NF-κB	proteins	has	so	far	been	of	little	value.	
There	are	existing	drugs	which	influence	alternative	pathway	NF-κB	signaling,	largely	by	“off	
target”	effects.	There	are	several	established	examples	in	which	the	mechanism	of	action	of	
the	drug	has	not	been	fully	characterized,	and	in	which	multiple	off-target	responses	may	be	
expected.	 Such	 drugs	 include	 sulfasalazine,	 which	 has	 been	 used	 for	 the	 treatment	 of	
ulcerative	colitis	since	the	1940s	(72),	and	which	has	been	shown	to	 inhibit	both	IKKα	and	
IKKβ	 (79).	 This	 phenomenon	 is	 not	however	 limited	 to	 established	drugs	with	 imprecisely	
defined	molecular	effects;	drugs	developed	in	the	precision	medicine	era	also	have	diverse	
effects	on	NF-κB	signaling.	The	most	well	studied	example	is	the	26S	proteasome	inhibitor	
Bortezomib.	 This	 drug	 non-selectively	 inhibits	 the	 kinase	 targeted	 breakdown	of	 signaling	
molecules	by	the	proteasome,	and	has	marked	effects	on	both	classical	and	alternative	NF-
κB	activation	pathways.	Bortezomib	is	effective	in	multiple	myeloma,	and	a	specific	subset	
of	patients	with	a	defined	NF-κB	dependent	pattern	of	transcription	has	been	identified	in	
whom	Bortezomib	is	particularly	effective.	However	as	this	agent	impacts	both	classical	and	
alternative	 NF-κB	 pathways,	 it	 is	 not	 possible	 to	 interpret	 how	 effective	 drugging	 the	
alternative	pathway	is	in	this	context.		
The	development	of	novel	drugs	that	specifically	target	alternative	pathway	NF-κB	signaling	
will	be	relatively	challenging	due	to	the	vast	number	of	downstream	effects.	It	is	therefore	
likely	 that	 to	 develop	 rational	 therapeutic	 strategies	 that	 target	 this	 signaling	 network,	
careful	modelling	of	upstream	regulatory	components	which	combine	to	trigger	specific	NF-
κB	responses	will	be	required.	For	this	reason,	future	investigations	of	potential	therapies	in	
this	area	will	need	to	move	beyond	simple	strategies	targeting	an	individual	component	of	
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the	 pathway	 towards	 an	 understanding	 of	 how	 the	 NF-κB	 signaling	 network	 is	 altered	 in	
different	disease	states.	Understanding	this,	and	the	regulatory	pathways	that	lead	to	these	
differences,	 will	 allow	 the	 identification	 of	 drugs	 that	 interfere	 with	 NF-κB	 signaling	 to	
promote	a	more	physiological	state.		
Discussion		
Several	 recent	 studies	 have	 highlighted	 the	 importance	 of	 alternative	 pathway	 NF-κB	
signaling	in	addition	to	the	more	widely	studied	classical	NF-κB	signaling	pathway	during	the	
development	and	progression	of	both	 inflammation-associated	cancers	of	the	GI	tract	and	
sporadic	 cancers	which	have	an	 inflammatory	element.	Some	elements	of	NF-κB	signaling	
pathways	and	their	implications	for	disease	have	been	well	characterized,	but	investigation	
in	 other	 areas	 is	 lacking	 (table	 1).	 In	 particular,	 gaps	 exist	 in	 our	 understanding	 of	 these	
pathways	 in	 the	 formation	 of	 esophageal	 cancers	 and	 the	 role,	 if	 any,	 played	 by	 the	
gastrointestinal	microbiome	in	regulating	them.	
Most	of	the	studies	reported	to	date	have	relied	on	relatively	imprecise	tools	to	characterize	
the	function	of	NF-κB	signaling	pathways,	for	instance	the	observation	that	NF-κB	activation	
events	may	be	localized	to	specific	anatomical	structures	within	in	the	GI	tract	(e.g.	Peyer’s	
patches)	 suggests	 that	 previous	 studies	 which	 have	 assessed	 NF-κB	 activation	 events	 in	
whole	tissue	preparations	should	be	interpreted	with	caution.	Many	investigations	have	also	
relied	on	either	transgenic	mice	in	which	the	stoichiometry	of	different	pathway	members	is	
fundamentally	altered,	or	have	used	semi-quantitative	analyses	of	protein	abundance	to	try	
to	explain	the	complexities	of	these	pathways.	
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Banoth	and	colleagues	have	demonstrated	a	different	approach	to	research	in	this	field	by	
employing	 systems	 medicine	 techniques	 to	 characterize	 interactions	 between	 multiple	
components	of	this	complex	transcriptional	regulating	machinery.	In	the	future,	increasingly	
complex	mathematical	modeling	will	be	required	to	better	understand	how	inflammation	is	
regulated	by	NF-κB	 signaling	 in	 real-time,	and	 to	apply	 these	models	 to	 complex	 systems,	
including	 the	 pathogenesis	 of	 cancer.	 To	 achieve	 this,	 close	 collaboration	 between	
researchers	with	diverse	backgrounds	including	clinician	scientists,	molecular	biologists	and	
systems	biologists	will	be	necessary.	
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Figure	Captions	
Figure	1	Classical	NF-κB	signaling	pathway	activation	by	receptor	binding	results	in	the	recruitment	
of	 RIP1	 (Receptor-interacting	 protein	 kinase	 1)	 to	 the	 receptor	 complex	 and	 subsequent	
ubiquitination	 of	 IKKγ	 and	 phosphorylation	 of	 IKKβ	 resulting	 in	 the	 activation	 of	 the	 IKK	 complex	
(consisting	 of	 IKKγ,	 IKKβ	 and	 IKKα).	 	 The	 IKK	 complex	 targets	 IκB	 for	 proteasomal	 degradation	
allowing	 classical	 NF-κB	 pathway	 dimers	 to	 translocate	 to	 the	 nucleus	 and	 activate	 target	 gene	
transcription.	 Regulators	 of	 the	 classical	NF-κB	 signaling	 pathway	 also	 include	A20	 (also	 known	as	
TNFAIP3),	 TAK	 (transforming	 growth	 factor	 β-activated	 kinase)	 and	 TAB	 (TAK	 binding	 protein)	 (a).	
Unlike	the	classical	pathway	of	NF-κB	activation,	the	alternative	pathway	is	normally	held	inactive	by	
the	continuous	proteasomal	degradation	of	NIK	mediated	by	the	ubiquitin-ligase	complex	consisting	
of	 E2,	 c-IAP	 1	 or	 2,	 TRAF	 2	 and	 3	 (b).	 Upon	 ligand	 binding	 receptor	 (eg	 CD40L),	 TRAF3	 is	
polyubiquitinated	by	 the	ubiquitin-ligase	 complex	 and	 targeted	 for	 proteasomal	 degradation,	 thus	
releasing	NIK	to	accumulate	in	the	cytoplasm.		NIK	phosphorylation	results	in	activation	of	NIK	kinase	
activity	 and	 both	 NF-κB2(p100)	 and	 IKKα	 are	 then	 phosphorylated	 by	 NIK	 allowing	 the	
homodimerisation	of	 IKKα.	 IKKα	homodimers	 further	phosphorylate	p100	at	 the	C-	and	N-	 termini	
resulting	 in	 ubiquitination	 and	 partial	 degradation	 of	 the	 p100	 NF-κB2	 subunit	 to	 mature	 p52	
protein.	 RelB-p100	 dimers	 are	 transcriptionally	 inactive,	 however	 following	 p100	 proteasomal	
processing,	RelB-p52	dimers	are	able	to	enter	the	nucleus	and	activate	transcription	(c).	
Figure	2	The	gastric	corpus	(a-d),	small	intestine	(e-h)	and	colon	(i-p)	of	untreated	Nfκb2-/-	mice	(b,	f,	
j,	 n)	 are	 phenotypically	 normal	 compared	 with	 C57BL/6	 wild-type	 mice	 (a,	 e,	 i,	 m).	 	 The	
administration	of	Helicobacter	felis	by	oral	gavage	results	in	extensive	pathology	in	the	gastric	corpus	
of	 C57BL/6	 mice	 12	 months	 following	 indicated	 by	 inflammatory	 infiltrate	 (arrows),	 parietal	 cell	
atrophy	(arrow	heads)	and	cystic	glands	(open	arrow	head)	(c).	 	The	 intraperitoneal	administration	
of	 0.125mg/kg	 lipopolysaccharide	 (LPS)	 to	 C57BL/6	 mice	 results	 in	 a	 rapid	 onset	 and	 increased	
abundance	 of	 small	 intestinal	 epithelial	 cell	 shedding	 and	 apoptosis	 1.5	 hours	 following	 and	 is	
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indicated	 by	 active	 caspase-3	 immunohistochemistry	 (g).	 Administration	 of	 2%	 dextran	 sulphate	
sodium	in	the	drinking	water	of	C57BL/6	mice	for	5	days	followed	by	3	days	of	recovery	on	normal	
drinking	water	results	 in	extensive	colonic	pathology	resembling	human	colitis	(k,	o).	 	Arrow	heads	
show	inflammatory	infiltrate	and	arrows	indicate	regenerating	colonic	crypts	(o).		However,	Nfκb2-/-	
mice	administered	with	the	same	treatments	do	not	show	such	severe	pathology	 in	gastric	corpus	
(d),	 small	 intestine	 (h)	 and	 colon	 (l,	 p)	 and	 are	 protected	 from	 injury	 induced	 by	 these	 stimuli.	
Original	magnifications:	16x	(a-h),	10x	(i-l)	and	25x	(m-p).											
	
Table	1	
Setting	 RELB	 NFKB2	
Protein	expression	in	the	gastrointestinal	
tract	
Murine	gastric	epithelium	[19].	
Peyer’s	patches,	including	follicle	
associated	epithelium	of	the	small	
intestine	[18].	
Murine	gastric	epithelium	[19].	
Gastrointestinal	phenotype	of	unstressed	
transgenic	mice	
No	published	data	 Mice	lacking	the	COOH-terminal	ankyrin	repeat	domain	
of	p100	exhibit	gastric	epithelial	hyperplasia	and	die	due	
to	gastric	outlet	obstruction	[30].	
Esophageal	carcinogenesis	 No	published	data	 Increased	abundance	of	NFKB2	protein	identified	in	
esophageal	tissue	from	patients	with	squamous	cell	
carcinoma	of	the	esophagus	[39].	
Gastric	carcinogenesis	 No	published	data	 Processing	of	p100	to	p52	in	B-lymphocytes	was	induced	
by	Helicobacter	pylori	co-culture	in-vitro	[50].	
Nfkb2-/-	mice	were	resistant	to	H.	felis	induced	
carcinogenesis	[19].	
Colon	carcinogenesis	 No	published	data	 Nfkb2-/-	mice	were	resistant	to	azoxymethane	and	pulsed	
dextran	sulphate	sodium	induced	colitis	associated	
adenoma	formation	[57].	
Gastrointestinal	infection	and	infestation	 No	published	data	 Nfkb2-/-	mice	developed	more	severe	colitis	in	response	
to	Citrobacter	rodentium	[17].	
Nfkb2-/-	mice	developed	chronic	persistent	infection	with	
Trichuris	muris,	in	contrast	to	wild-type	mice	which	
spontaneously	clear	the	infestation	[59].	
Inflammatory	Bowel	Disease	 No	published	data	 Nfkb2-/-	mice	were	resistant	to	both	DSS	induced	colitis	
and	lipopolysaccharide	induced	epithelial	cell	apoptosis	
and	shedding	[71,	57].	
Celiac	disease	 No	published	data	 An	increase	in	the	expression	of	NFKB2	has	been	
identified	in	tissue	from	patients	with	celiac	disease,	this	
has	yet	to	be	correlated	with	disease	pathogenesis	or	
response	to	gluten	free	diet	[76].	
	


